Buy Nimbex ampoules 2 mg/ml, 2.5 ml, 5 pcs
  • Buy Nimbex ampoules 2 mg/ml, 2.5 ml, 5 pcs

Cisatracurium besylate

GlaxoSmithKline
1513 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$86.56
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Muscle relaxant, non-depolarizing. Nimbex binds to the n-cholinergic receptors of motor nerve endings and acts as an acetylcholine antagonist, causing a competitive blockade of neuromuscular conduction, which can be quickly eliminated by anti-cholinesterase agents such as neostigmine and edrofoniya. The effect of Nimbex on patients with malignant hyperthermia in history has not been studied.

Indications

Myorelaxation during surgery, tracheal intubation, mechanical ventilation.

Composition

1 ml. contains cisatracuria besyat 2 mg.

No customer reviews for the moment.

Write your review

Write your review

Cisatracurium besylate

Dosage and Administration

Intravenous, bolus. In adults and in children from 1 month. up to 12 years for tracheal intubation - 0.15 mg / kg, quickly, within 5-10 s. 2-3 minutes after the injection, there is a neuromuscular block sufficient for tracheal intubation. With the introduction of higher doses, the block comes faster. Sequential administration of maintenance doses does not lead to a progressive increase in the duration of the effect. After the spontaneous recovery of the neuromuscular block has begun, its speed does not depend on the total dose administered.

Contraindications

Hypersensitivity to cisatracuria, atracuria, and benzenesulfonic acid, a child's age (up to 2 years). With caution: disruption of EC or electrolyte balance, burns, carcinomatosis, neuromuscular diseases (including myasthenia, myasthenic syndrome) or other conditions, which can lead to prolonged neuromuscular blockade, hemiparesis, paraparesis, pregnancy, lactation.

Drug interactions

The effect strengthens drugs for inhalation general anesthesia (halothane, ether), other non-depolarizing muscle relaxants; antibiotics (aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin and clindamycin); antiarrhythmic drugs (propranolol, BMCC, lidocaine, procainamide, quinidine); diuretics (furosemide, thiazides); salts MD2 +, salts Li +; ganglion-blocking drugs (trimetafan, hexametonium). The previous long-term use of phenytoin or carbamazepine - weakening the effect of the drug. Prior administration of suxamethonia does not affect the duration of the neuromuscular block. The introduction of suxamethonia in order to increase the duration of the neuromuscular block caused by non-depolarizing muscle relaxants can lead to a long and complex blockade, which can be difficult to eliminate with the help of anticholinesterase drugs. Incompatible with ketorolac, trometamol, propofol.

Special instructions

Dose adjustment is not required in elderly patients, in patients with impaired renal function, liver, or with CVD diseases. The drug causes paralysis of the respiratory and other skeletal muscles, but does not affect the mind or the pain threshold. It should be administered only by an anesthesiologist or a specialist with experience in the use of muscle relaxants, with the possibility of tracheal intubation, mechanical ventilation and adequate oxygenation of the blood. When diluted in Ringer's lactate solution, the injection drug is chemically unstable, stable only in acidic solutions, so it should not be mixed in one syringe or injected simultaneously through a single needle with alkaline solutions, for example sodium thiopental.

Overdosage

Symptoms: the expected symptoms are due to prolonged paralysis of the respiratory muscles and its consequences.

Treatment: It is very important to maintain the ventilation and oxygenation of the blood until the restoration of adequate spontaneous respiration. If signs of spontaneous neuromuscular conduction recover, it can be accelerated by administering anticholinesterase drugs.

  • Brand name: Nimbex
  • Active ingredient: Cisatracurium besylate
  • Dosage form: Injection
  • Manufacturer: GlaxoSmithKline
  • Country of Origin: Great Britain

Studies and clinical trials of Cisatracurium besylate (Click to expand)

  1. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products
  2. Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro
  3. Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate
  4. The effect of different storage temperature on the pharmacodynamic dose-response of cisatracurium besylate
  5. Dose–Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children during Nitrous Oxide–Narcotic Anesthesia
  6. Dose-Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children During Nitrous Oxide-Narcotic Anesthesia
  7. Capillary electrophoresis with electrochemiluminescence detection for the simultaneous determination of cisatracurium besylate and its degradation products in pharmaceutical preparations
  8. Preclinical pharmacology of cisatracurium besylate
  9. Pharmacokinetics and Pharmacodynamics of a 0.1 mg/kg Dose of Cisatracurium Besylate in Children During N2O/O2/Propofol Anesthesia
  10. Influence of Acute Normovolaemic Hemodilution on the Dose-Response Relationship and Time Course of Action of Cisatracurium Besylate
  11. Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury
  12. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures
  13. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration

8 other products in the same category:

arrow_upward